-

04:06:22 AM

CSLLY Stock News

CSLLY - CSL Ltd.

11/28/22 1:00 AM

OTC : GNHAY, CSLLY

low float

Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients

Regulatory News:. “We are thrilled about the marketing authorization of Ferinject ®, which is a milestone for Chinese patients living with iron deficiency or iron deficiency anemia”, said Hervé Gisserot, General Manager of CSL...

RHEA-AI

neutral

11/22/22 3:59 PM

OTC, Nasdaq : CSLLY, QURE

fda approval

U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B

- This historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates elevated and sustained factor IX levels for years after a one-time infusion- With the approval of HEMGENIX, CSL now offers an

RHEA-AI

positive

11/02/22 6:30 PM

OTC : CSLLY

acquisition

Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022

RHEA-AI

neutral

11/01/22 6:05 PM

Nasdaq, OTC : ARCT, CSLLY

Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced a strategic collaboration with CSL Seqirus, a global vaccine leader, for the research, development,...

RHEA-AI

neutral

10/20/22 1:00 AM

OTC : GNHAY, CSLLY

low float

Approval of extension of exemptions from SIX disclosure and publicity obligations

Regulatory News:. Vifor Pharma AG announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG has approved an extension of the various exemptions from certain disclosure and publicity obligations granted by SER to Vifor Pharma AG previously. "I. Die Vifor Pharma AG wird im Hinblick auf die geplante Dekotierung bis...

RHEA-AI

neutral

10/12/22 1:00 AM

OTC : GNHAY, CSLLY

low float

Approval of delisting of Vifor Pharma AG's registered shares

Regulatory News:. Vifor Pharma AG announced today that Vifor has received approval for the delisting of the totality of Vifor's registered shares.

RHEA-AI

neutral

10/11/22 12:35 PM

OTC : CSLLY

CSL Plasma Expands in California with New Donation Centers to Collect Life-Saving Plasma

CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, today announced

RHEA-AI

neutral

10/06/22 12:00 PM

OTC : CSLLY

CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine

CSL Seqirus will manufacture and clinically assess a cell-based, adjuvanted pre-pandemic influenza vaccine candidate to support the U.S. government's pandemic preparedness activities Third influenza pandemic preparedness award to CSL Seqirus under a multi-year agreement with Biomedical Advanced

RHEA-AI

positive

10/05/22 8:30 AM

OTC : CSLLY

clinical trial

CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Global biotech leader CSL (ASX:CSL) today announced

RHEA-AI

neutral

09/26/22 8:00 AM

OTC : CSLLY

New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems

CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data from four real-world studies showing the impact that cell-based and adjuvanted influenza vaccines can have in reducing the burden of seasonal influenza on hospitals and health

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next